Research programme: stem cell therapeutics - BioRestorative Therapies

Drug Profile

Research programme: stem cell therapeutics - BioRestorative Therapies

Alternative Names: BRTX-100; brtxDISC; ThermoStem

Latest Information Update: 13 Jan 2017

Price : $50

At a glance

  • Originator BioRestorative Therapies
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cardiovascular disorders; Diabetes mellitus; Hypertension; Intervertebral disc degeneration; Metabolic disorders; Obesity

Most Recent Events

  • 09 Jan 2017 Preclinical development in Cardiovascular-disorders, Metabolic-disorders, Diabetes-mellitus, Obesity and Hypertension in USA (Injection, Implant)
  • 09 Jan 2017 BioRestorative Therapies files an IND application with the US FDA for Intervertebral disc degeneration in USA
  • 09 Feb 2016 BioRestorative Therapies plans to file an IND application with the US FDA for Intervertebral disc degeneration in USA in 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top